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Abstract
Raynaud’s phenomenon (RP) is frequent in autoimmune connective tissue diseases (AICTD) and its approach includes 
nailfold capillaroscopy (NFC), as it is a non-invasive technique that permits direct visualization of the microcirculation. The 
aim of this study is to analyze and establish clinical correlations between NFC findings and particular aspects of autoim-
mune disorders. This is a retrospective study. Clinical data from patients attending our NFC clinic were reviewed. Inclusion 
criteria included AICTD previous diagnosis, which included systemic sclerosis (SSc), mixed connective tissue disease 
(MCTD), systemic lupus erythematosus (SLE), Sjögren syndrome, inflammatory idiopathic myopathies (IIM), rheumatoid 
arthritis, undifferentiated connective tissue disease and antiphospholipid syndrome (APS).  Videocap® version 3.0 biomi-
croscope was used. NFC score was determined. For statistics, SPSS software was utilized. 384 patients were included; most 
of them were women, with mean age of 47 years. RP was present in 91% of the patients, with greater prevalence in SSc and 
MCTD. Scleroderma pattern was the most prevalent NFC pattern, mainly in SSc, MCTD and IIM. Mean capillary density 
was reduced in IIM, SSc and MCTD. NFC score was worse in SSc, IIM and MCTD. In patients with AICTD, RP is related 
to microvascular damage and worse NFC score. NFC scleroderma pattern correlates with SSc classification criteria score. 
In MCTD, scleroderma pattern relates to myositis. SLE and APS reveal significant hemorrhages, but not related to APS 
antibodies. This study highlights the possible role of NFC as biomarker of AICTD, particularly in SSc and IIM.
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Introduction
Raynaud’s phenomenon (RP) is a frequent vasomotor phe-
nomenon, occurring discoloration of extremities due to 
vasospasm provoked by cold or stress—biphasic RP; in 
some situations, there’s a third phase, of hyperemia, due to 
reperfusion, which can be painful, and lasts a few seconds—
three-phase RP. It is a common manifestation in autoimmune 
diseases (AICTD), with a prevalence as high as 19% [1]. 
Nailfold capillaroscopy (NFC) is as non-invasive, safe, sim-
ple and low-cost technique used in the evaluation of patients 
with RP. As it permits a direct visualization of the microcir-
culation, morphologic abnormalities can be easily detected.
NFC is usually performed with a videocapillaroscope 
with magnifications lens (up to ×100, ×200 and ×600), 
which enables detailed observations of the distal capillary 
row. A normal field of observations usually measures 1 mm2. 
Normal capillaries have the shape of hairpin loops, parallel 
to the axis of the finger, with normal range of 7–12/mm2 
[2]. Qualitative assessment establishes the general pattern, 
allowing the distinction between primary and secondary 
RP, and scleroderma or non-scleroderma pattern, according 
to Cutolo et al. [3]. Three scleroderma patterns have been 
described: early, active and late. Early pattern presents few 
giant capillaries, few capillary microhemorrhages, normal 
density and absence of ramified capillaries; active pattern 
presents frequent giant capillaries and hemorrhages, mod-
erate loss of capillaries and absent ramified capillaries; late 
pattern presents severe loss of capillaries, extensive avascu-
lar areas, intensive vascular plexus distortion and ramified 
capillaries [4]. Semi-quantitative assessment is obtained by 
measuring particular characteristics of individual capillaries 
and its general counting—number of capillaries per field, 
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presence of dilated or giant capillaries, presence of hemor-
rhages, dimension of capillary limb or abnormally shaped 
capillaries (tortuosities, meandering, crossing, bifurcations 
or ramified branches, the latter representing “neoangiogen-
esis”) [2]. NFC score rates the capillaroscopic abnormali-
ties from 0 to 3, according to variations in density, dimen-
sion, morphology or hemorrhages [5]. Score zero defines 
no changes in NFC; score one (minor) defines mild changes 
(normal density, 10% longer capillaries, 50% of morpho-
logical changes, absence of hemorrhages); score two (major) 
defines major changes (normal or decreased density, 10% of 
elongated capillaries, 50% of morphological changes, pres-
ence of hemorrhages); score three (severe) defines severe 
changes (decreased density, 10% elongated capillaries, 75% 
morphological changes, presence of hemorrhages).
In AICTD, RP can be the earliest clinical manifestation, 
providing an opportunity to identify patients in an early stage 
of the disease and then implement an early treatment. NFC 
can also act as a predictor of RP severity in digital ulcera-
tions, using Capillaroscopic Skin Ulcer Risk (CSURI) in 
Systemic Sclerosis (SSc), validated in 2012 [6].
The aim of this study is to compare the experience of our 
clinic to the findings already described for each AICTD. 
Secondary objectives include establishment of clinical cor-
relations between particular NFC findings and phenotypi-
cal aspects of each of these diseases. As the majority of 
AICTD are rare disorders, disclosing information from dif-
ferent regions can contribute to a better understanding of 
microcirculation variations in distinct populations. To our 
knowledge, this is the most in-depth study in a Portuguese 
population.
Methods
A retrospective study was performed. Clinical data from 
patients attending the NFC clinic of an autoimmune dis-
eases unit from 2011 through 2017 were obtained and then 
anonymized. Patients were referred to capillaroscopy clinic 
from several different hospitals and private medical practice. 
Requests included clinical aspects to justify NFC evaluation 
like RP+, associated or not (RP−) with an autoimmune con-
nective tissue disease (AICTD), ischemic lesions, isolated 
positive autoantibody results or other systemic diseases with 
vascular involvement.
Inclusion criteria included previous diagnosis of connec-
tive tissue AICTD or antiphospholipid syndrome, based on 
validated international criteria (systemic sclerosis (SSc)—
2013 ACR/EULAR SSc criteria; systemic lupus erythema-
tosus (SLE)—1997 ACR criteria; mixed connective tissue 
disease (MCTD)—Alarcón-Segovia diagnostic criteria; 
rheumatoid arthritis (RA)—2010 ACR/EULAR Criteria; 
Sjögren Syndrome (SSj)—2016 ACR/EULAR criteria for 
primary SSj; antiphospholipid syndrome (APS)—2006 
International Classification Criteria; Undifferentiated Con-
nective Tissue Disease (UCTD)—classification criteria 
proposed by Mosca et al. in 1999; dermatomyositis and 
polymyositis—2017 EULAR/ACR Classification Criteria 
for Idiopathic Inflammatory Myopathies) [7–15]. Exclu-
sion criteria included patients with other AICTD, including 
vasculitis, unfulfillment of diagnostic criteria, undiagnosed 
situations or missing data impossible to retrieve in patient’s 
electronic file.
Analyzing variables comprised demographics (gender, 
age at the examination), presence/absence of RP, relevant 
clinical aspects, immunologic results, risk factors for RP 
non-related to AICTD (tobacco use, hormone therapy, finger 
microtrauma caused by professional occupation or hobbies), 
ongoing treatment and NFC result.
All patients stood in a 22 °C acclimatized waiting room 
before the exam, for at least 15 min, to avoid RP attacks. 
All NFCs were performed with a  Videocap® biomicroscope 
version 3.0, magnification 200×, using sweet almond oil to 
smooth and improve visualization of the skin. NFC was 
performed on eight fingers, four fingers from each hand, 
excluding the thumbs (due to opponency’s frequent trauma 
and thicker skin), capturing at least four images per finger. 
Results were validated by two different physicians attend-
ing the NFC clinic. Qualitative assessment criteria followed 
Cutolo et al. classification, dividing patterns as scleroderma 
and no scleroderma [16, 17]. Minor morphological abnor-
malities included tortuosities, crisscrossing and dilated 
loops; major abnormalities included giant, branched (neo-
angiogenesis) and twisting (meandering) capillaries. As for 
quantitative assessment, capillaries with distal loop ≥ 30 µm 
were considered dilated; if mean diameter was ≥ 50 µm, cap-
illaries were considered giant capillaries [16]. Elongated 
capillaries were considered if loops were longer than 300 µm 
[18]. Density was obtained calculating the mean capillary 
number in the distal row by  mm2. Normal density is consid-
ered normal between 7 and 12 capillaries/mm2.
Descriptive statistical analysis used means and standard 
deviation (SD) for clinical and demographics characteristics, 
as well as frequencies and percentages for qualitative vari-
ables. Chi-square test with Yates’s correction, Fisher exact 
test, independent T test not assuming equal variances and 
one-way ANOVA were used for correlation and variance 
analysis, with p value < 0.05.  SPSS® software was used.
Results
About 1148 NCF were performed, but 764 results were 
excluded for lacking major relevant data, as immunologic 
profile, for example.
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A total of 384 NCF were included in this study 
(Table 1), most of them in women (91%), with a mean 
age of 47 (± 17) years. Some patients accomplished diag-
nostic criteria for more than one disease, as secondary 
APS in SLE, accounting for both of them. The most fre-
quent AICTD diagnosed at the moment of the exam was 
SSc (36%), followed by UCTD (16%) and SLE (15%). 
RP was present in approximately 91% of patients, with 
greater prevalence in SSc (100%) and MCTD (97%). The 
presence of RP was strongly related to an abnormal NFC 
result (p < 0,001) and a worst NFC score (p < 0.001).
Qualitative analysis disclosed scleroderma pattern in the 
majority of patients (54%), although non-scleroderma pat-
tern was more frequent in SLE (79%), SSj (67%), RA (91%), 
UCTD (81%) and APS (67%). Quantitative assessment of 
NFC revealed decreased density of capillaries and more 
avascular areas in SSc, IIM and MCTD. Although dilated 
loops were frequently found in all AICTD, except for SLE, 
giant capillaries were predominant in SSc (94%), IIM (79%) 
Table 1  Main characteristics of the study population, according to each previously diagnosed autoimmune disease
NFC nailfold capillaroscopy, SSc systemic sclerosis, MCTD mixed connective tissue disease, SLE systemic lupus erythematosus, IIM inflam-
matory idiopathic myositis, RA rheumatoid arthritis, UCTD undifferentiated connective tissue disease, APS antiphospholipid syndrome, RP+ 
Raynaud’s phenomenon present
Variable SSc MCTD SLE SSj IIM RA UCTD APS Total
n (%) 137 (35.68) 38 (9.90) 58 (15.10) 15 (3.91) 24 (6.25) 22 (5.73) 62 (16.15) 45 (11.72) 384 (100.00)
Mean age 
(years)
53.81 ± 15.80 39.95 ± 19.85 41.93 ± 14.42 49.53 ± 16.24 37.17 ± 22.01 53.32 ± 12.45 47.15 ± 15.26 42.69 ± 13.72 47.38 ± 16.98
Female (%) 93.43 86.84 93.10 100.00 91.67 90.91 87.10 91.11 91.15




94.16 68.42 12.07 33.33 83.33 4.55 14.52 28.89 53.65
 Non-sclero-
derma
5.84 28.95 79.31 66.67 8.33 90.91 80.65 66.67 39.06




















94.16 68.42 12.07 33.33 79.17 13.64 16.67 28.89 53.65
 Elongated 
(%)




9.49 15.79 39.66 26.67 8.33 31.81 16.67 17.78 32.03
 Crossing 
(%)
56.20 73.68 93.10 100.00 50.00 100.00 95.16 91.11 76.30
 Tortuosities 
(%)








46.72 39.47 8.62 0.00 58.33 4.55 11.29 20.00 29.17
NFC score 
(mean)
2.41 1.97 1.59 1.67 2.34 1.82 1.45 1.64 1.96
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and MCTD (68%). Elongated capillaries were scarce, but 
more frequent in SSj (27%), UCTD (24%) and RA (18%). 
Minor abnormalities were frequent in every AICTD, with 
particular emphasis on tortuosities (92%). Hemorrhages 
and neoangiogenesis were present mainly in SSc, IIM and 
MCTD.
Considering each AICTD separately, all the selected 
SSc patients fulfilled the ACR/EULAR classification crite-
ria, with a mean of 14.24 points/patient (≥ 9 points makes 
the diagnosis of SSc). RP [n = 137 (100.0%)], abnormal 
NFC findings [n = 126 (92.0%)] and sclerodactyly [n = 108 
(78.8%)] were the most frequent criteria; anti-centromere 
antibody was the most prevalent autoantibody. Active scle-
roderma pattern was the most frequent result on qualitative 
assessment of NFC results.
Patients revealing a scleroderma pattern on NFC pre-
sented a higher score on 2013 ACR/EULAR classification, 
which means either more severe manifestations of the dis-
ease or greater disease activity. Greater severity of sclero-
derma pattern, as active or late pattern, strongly related to 
a higher classification criteria score (p < 0.001). No rela-
tion was found between each SSc autoantibody and a par-
ticular scleroderma pattern (p > 0.05), except for anti-RNA 
polymerase III antibody and active scleroderma pattern 
(p = 0.04).
In MCTD, hand edema was present in 25 (66%) patients, 
synovitis in 28 (74%), myositis in (26%), RP in 36 (95%) 
and acrosclerosis in 26 (68%). The main NFC pattern was 
scleroderma—early in 10 patients, active in 12 and late in 
4. There was no relation between clinical aspects related to 
classification criteria of MCTD and the NFC pattern, except 
for myositis and scleroderma pattern (p value = 0.04).
In SLE patients, arthritis was the most frequent clinical 
criteria (50%, n = 29), followed by malar rash (47%, n = 27), 
photosensitivity (43%, n = 25) and renal disorder (33%, 
n = 19). As for immunologic markers, anti-nuclear antibody 
was positive in 98% (n = 57), anti-double-stranded DNA 
in 57% (n = 33), anti-cardiolipin antibody in 17% (n = 10), 
anti-beta-2 glycoprotein in 17% (n = 10) and lupus antico-
agulant in 31% (n = 18) patients. The main NFC pattern was 
non-scleroderma (79%) and the most frequent capillaros-
copy findings were minor abnormalities, like crossing (93%) 
and tortuosities (98%), and hemorrhages (52%). About 33% 
(n = 19) of patients were positive for Anti-SSA antibody 
(A-SSA+). The relation between antiphospholipid antibod-
ies and hemorrhages was negative (p = 0.64). No relation 
was found between A-SSA+ and the presence of hemor-
rhages (p = 0.85); between RP+ and dilated loops (p = 0.13) 
or RP+ and hemorrhages (p = 0.92).
RP was present in 93% of SSj patients and non-sclero-
derma pattern was the most frequent NFC result. Crossing 
and tortuosity were observed in all patients. Most patients 
presented primary SSj (73%), while 27% had secondary SSj 
(associated with MCTD, overlap to primary biliary cirrhosis 
and Achenbach syndrome). Secondary SSj related to scle-
roderma pattern (p < 0.001) and hemorrhages (p = 0.03) in 
NFC. Scleroderma pattern was not related to RP (p = 0.649).
IIM included patients with polymyositis (n = 3), dermato-
myositis (n = 17) and anti-synthetase syndrome (n = 4). All 
patients with DM and ASSD presented scleroderma pattern; 
all PM had non-scleroderma pattern. RP and scleroderma 
pattern were present in 75% and 83% patients, respec-
tively. No significative association was established between 
scleroderma pattern and RP (p = 0.116), Gottron papules 
(p = 0.855) or anti-Jo1 antibodies (p = 0.186). Mean NFC 
score was 2,34.
RA patients revealed RP in 86%; non-scleroderma pat-
tern was present in 82%. Crossing and tortuosities were also 
present in all patients. Seropositivity for RA (rheumatoid 
factor or anti-citrullinated C peptide) was not related to scle-
roderma NFC pattern (p = 0.515). Neoangiogenesis was not 
visualized in RA patients.
Raynaud’s phenomenon was present in 87% UCTD 
patients and non-scleroderma pattern in 81%. No relation 
was found between RP and scleroderma pattern (p = 0.414).
In APS, RP was present in 82% of patients and non-scle-
roderma pattern prevailed on NFC results. Primary APS 
accounted for 36% of patients; secondary APS was mostly 
associated with SLE and MCTD. No correlation was found 
between primary or secondary APS and scleroderma pat-
tern (p = 0.959) or presence of hemorrhages (p = 0.887). 
Hemorrhages were not associated with ongoing antico-
agulation treatment (p = 0.07). However, the presence of 
microbleeding distributed symmetrically, the “comb-like” 
hemorrhages, was strongly associated with the diagnosis of 
APS (p < 0.001). Each antibody was tested for its association 
with hemorrhages: no relation was found with lupic anti-
coagulant (p = 0.102) or anti-β2-glycoprotein1 (p = 0.084); 
anti-cardiolipin antibody was associated with absence of 
hemorrhage (p = 0.048).
Tobacco use was present in 62 patients, mainly in SLE 
(n = 23) and SSc (n = 15) patients. No association was found 
between tobacco use and NFC Score (p = 0.249), or tobacco 
use and scleroderma pattern (p = 0.757). Analyzing specifi-
cally SSc patients, there was no association between tobacco 
use and worse NFC score (p = 0.994), scleroderma pattern 
(p = 0.773) or even worse scleroderma pattern (p = 0.218).
Discussion
This is a small and heterogeneous population, as only 
patients presenting an already-known AICTD at the exam 
were included. Strict fulfillment of the above-mentioned 
diagnostic criteria also reduced the population cohort. Fur-
thermore, many patients were referred to NFC after a single 
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medical consultation, so that diagnostic workup was still 
ongoing. As NFC is part of the RP approach, there is a bias 
on the frequency found for RP in the included AICTD. So, 
the percentage of RP in our patients cannot be inferred as 
the relative frequency of RP in AICTD patients.
Women were more affected, as AICTD and RP are known 
to be more frequent on female gender [19]. This study con-
firms that autoimmune disorders clearly present NFC abnor-
malities and that RP is a frequent symptom, which, itself, 
relates to worse NFC score. Scleroderma pattern was the 
most frequent NFC pattern, but SSc and MCTD patients 
were also the most prevalent groups. NFC score was worse 
on SSc and IIM, as scleroderma pattern is also more frequent 
in these AICTD, as stated before. Findings as hemorrhages 
and neoangeogenesis were also more prevalent in SSc and 
MCTD, reflecting vascular instability of giant capillaries, 
which leads to spontaneous rupture, avascular areas and new 
ramified capillaries (neoangiogenesis).
In systemic sclerosis (SSc), RP is present in almost every 
patient, with prevalence higher than 95%, either in limited 
cutaneous SSc (lcSSc) or diffuse cutaneous SSc (dcSSc) 
[20]. NFC is particularly important in SSc, as giant capil-
laries account for classification criteria, scoring 2 points out 
of a minimum of nine [7]. The microvascular damage in 
SSc evolves by progressive dilation of the distal loop and 
decrease in its density, slow blood flow, hemorrhages and 
neoangiogenesis. We found that greater severity of NFC 
scleroderma pattern positively correlates with the number 
of SSc classification criteria—which, itself, already includes 
changes in NFC and vascular complications, as digital 
ulcers. NFC changes witness microvascular damage. There-
fore, this result supports the assumption that NFC findings 
relate to systemic involvement and disease progression. SSc 
autoantibodies were only associated with active scleroderma 
pattern in anti-RNA polymerase III antibody.
In Mixed Connective Tissue Disease (MCTD), RP is also 
very frequent, with prevalence higher than 90%, although 
digital ischemia and ulceration are rare when compared with 
SSc [21]. RP is an important symptom in MCTD, often the 
only one present at the diagnosis, and accounts as classi-
fication criteria in Alarcon-Segovia, Sharp and Kasukawa 
criteria [22–24]. NFC usually reveals a scleroderma pattern, 
which has been associated with the development of internal 
organ damage [25]. In fact, MCTD patients mostly presented 
a scleroderma pattern, which in turn relates to myositis. 
To our knowledge, this is the first time this association is 
described and it clearly suggests microvascular damage in 
inflammatory idiopathic myositis, albeit the sample size.
Systemic lupus erythematosus (SLE) has a prevalence of 
RP of 18-40% and it may appear before or after the diagnosis 
[26, 27]. RP is associated with organ complications and pos-
itivity for anti-cardiolipin (IgG) antibody [28]. A recent sys-
tematic review concluded that SLE patients presented more 
tortuous and abnormal capillaries, with more hemorrhages 
and higher NFC score than healthy controls [27]. It also 
related SLE disease activity with NFC abnormalities, but 
based on small sample cohorts. In this study, SLE NFC score 
particularly reaches level 2, probably due to the presence 
of hemorrhages. However, no relation was found between 
hemorrhages and APS autoantibodies. These hemorrhages 
could have been mistakenly interpreted as resulting from 
spontaneous rupture, instead of microtrauma. Nevertheless, 
all patients were carefully asked about their jobs, hobbies 
and even onychophagia, to more easily recognize traumatic 
hemorrhages. A possible explanation is that these patients 
present a great proportion of morphologic abnormalities, as 
crossing and tortuosities, and this capillary instability can 
more easily lead to spontaneous capillary rupture and conse-
quent hemorrhages. SLE patients presented a predominance 
of cutaneous manifestations, which can be due to sensitivity 
of 1997 ACR diagnostic criteria. These criteria were chosen 
over the 2012 SLICC criteria, once great part of the patients 
was previously diagnosed using 1997 criteria [8].
RP is a common clinical sign in Sjögren’s syndrome 
(SSj) and appears in up to one-third of patients, albeit digital 
ischemic complications are rare [29, 30]. NFC abnormali-
ties range from non-specific findings, like crossing, to more 
specific ones, as hemorrhages, and even scleroderma-type 
changes, which are more frequent in patients with RP [31]. 
In our sample, secondary SSj positively relates to sclero-
derma patterns, but those patients had overlap syndromes, 
also presenting diseases as MCTD and PBC [32]. In these 
cases, one must relate the NFC results to primary or second-
ary diagnosis.
The frequency of RP in idiopathic inflammatory myopa-
thies (IIM) is 20% in polymyositis (PM), 40% in dermatomy-
ositis (DM) and 62% in anti-synthetase syndrome (ASSD) 
[33, 34]. NFC is usually more exuberant in DM. A study 
by Manfredi A et al. revealed that capillaroscopic findings 
(mainly capillary loss, giant, bushy and ramified capillaries) 
were clearly associated only to DM, while no significant 
difference was observed between PM and controls [35]. 
Recently, NFC abnormalities in ASSD were observed in 
up to 62% patients and scleroderma pattern was associated 
with positive anti-Jo1 autoantibody, but not to Raynaud’s 
phenomenon [36]. In our IIM patients, results were in line 
with previous descriptions: all the DM and ASSD patients 
presented scleroderma pattern and all the PM’s a non-scle-
roderma pattern.
RP is present in rheumatoid arthritis (RA) in 5–17%, 
depending on the series [37, 38]. Angiogenesis and tortuos-
ity account for the most frequent NFC findings, according to 
a recent study including 430 RA patients [39]. RA patients 
presented mainly a non-scleroderma pattern, as predictable, 
and exuberant minor abnormalities, like crossing and tortu-
osities. In RA, microcirculation involvement can result from 
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inflammation, endothelial dysfunction or atherosclerosis [40, 
41]. The fact that almost 91% of our patients revealed capil-
lary abnormalities and dysfunction suggests that microcircu-
lation in RA can also be involved and its pathology process 
has yet to be elucidated.
In undifferentiated connective tissue disease (UCTD), 
RP occurs in about half patients and was associated with 
esophageal dysmotility and anti-ribonucleoprotein antibod-
ies [42, 43]. Patients presenting RP also present more NFC 
abnormalities, such as widened and irregular enlarged capil-
lary loops. In this study, non-scleroderma pattern prevailed 
on UCTD patients, and no relation was found between RP 
and scleroderma pattern. However, the great proportion of 
patients with RP justifies a close follow-up and repeated 
NFC exams, to early detect any change that can disclose any 
disease evolving into a different AICTD.
RP has been described in association with APS in anec-
dotic reports and the prevalence of primary or secondary 
RP has not yet been established. Studies referring NFC in 
APS concluded that microhemorrhages appear to correlate 
to clinical manifestations, although it does not suffice for its 
diagnosis, due to relative low sensitivity and specificity [43]. 
A special pattern of microbleeding distributed symmetrically 
has been described in patients with APS—the “comb-like” 
hemorrhages [44, 45]. Analyzing all the patients from our 
population who presented comb-like hemorrhage, it strongly 
correlated with previous APS diagnosis. Again, this particu-
lar NFC finding can be a part of the APS clinical condition 
and NFC should be performed in all APS patients.
Tobacco is known for its association with microvascular 
damage [46]. In our study, only a small proportion of the 
patients with AICTD smoked and evidence was not found 
between tobacco use and worse NFC outcomes.
Our study has some weaknesses and strengths. As men-
tioned above, the missing data greatly reduced our popu-
lation cohort, to strictly respect the classification criteria. 
Besides, as patients were frequently referred to our NFC 
clinic due to RP, there is a possible bias on its prevalence in 
the included AICTD. On the other hand, we carefully com-
pared our findings to those already described and we believe 
we are sharing valuable information about microcirculation 
in AICTD, which are rare diseases. We describe, for the first 
time, an association between scleroderma pattern in MCTD 
and muscle involvement; our patients with RA and UCTD 
also revealed great NFC abnormalities, which justifies fur-
ther research.
Conclusion
In conclusion, this small study emphasizes the importance 
of NFC as a possible biomarker on the approach of AICTD, 
as RP is a frequent symptom among them. As for SSc, the 
presented results suggest a correlation between NFC find-
ings and systemic involvement, underlining the possible role 
of NFC to witness or even predict disease progression. In 
MCTD, a new correlation was found between scleroderma 
pattern and myositis. IIM, specially DM and ASSD, reveal 
profound microvascular damage, so that NFC should be 
inherent on regular clinical investigations. In RA, microvas-
cular involvement has been disclosed and future research is 
needed to clarify its role in the disease development. UCTD 
patients should be carefully followed and monitored, as their 
disease can evolve, given the microcirculation involvement 
we have found. In APS, NFC can suggest but not establish 
the diagnosis, although it could be included in APS clinic 
approach. Larger studies are needed to obtain more statisti-
cally significant data.
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